帕利皮里对血清D-二次体水平的影响:临床和实验发现
Tingting Mou1, Jianbo Lai2, Lingzhuo Kong2
1Department of Psychiatry, The First Affiliated Hospital, Zhejiang University School of Medicine, 310003 Hangzhou, Zhejiang, China; Zhejiang Key Laboratory of Precision Psychiatry, 310003 Hangzhou, Zhejiang, China.
Actas espanolas de psiquiatria
|October 21, 2025
概括
帕利佩里在早期精神分裂症患者和小鼠的治疗中对D-二元水平的影响很小. 在治疗早期的小鼠中观察到过渡性减少,这表明要仔细监测凝血变化.
科学领域:
- 药理学 药理学是指药理学的学科.
- 血液学 血液学 血液学
- 精神病学是一个精神病学.
背景情况:
- 抗精神病药物可以影响凝血,但机制尚不清楚.
- 帕利佩里是一种用于治疗精神分裂症谱系障碍的非典型抗精神病药物.
- 帕利佩里对D-二聚体等凝血标记物的影响需要进一步研究.
研究的目的:
- 为了研究短期帕利佩里治疗对血清D-二聚合物水平的影响.
- 在早期精神分裂症治疗中评估与帕利佩里相关的潜在凝血失调.
主要方法:
- 人类研究:9名患有第一发精神分裂症的患者接受了为期2周的帕利佩里治疗;治疗前和后测量了D-二次体水平.
- 动物研究:8只小鼠每天接受帕利佩里 (3毫克/公斤) 10天;在第5天和第10天测量D-二元水平.
- 对照组:8只小鼠没有接受任何治疗;第10天测量了D-二次数.
主要成果:
- 在帕利佩里治疗后,在人类患者中没有发现D-二聚物水平的显著变化.
- 在小鼠中,与基线和对照组相比,D-二聚物水平在第五天显著降低.
- 在第10天的帕利皮里治疗小鼠和对照小鼠之间没有观察到D-二聚合物水平的显著差异.
结论:
- 短期帕利皮里治疗对人类和小鼠的血清D-二聚物水平的影响很小.
- 在小鼠中,在帕利佩里治疗的早期观察到过渡性降低的D-二聚合物水平.
- 在抗精神病治疗期间,临床医生应保持意识到药物诱导的潜在凝血变化.
相关概念视频
01:21Peripheral Arterial Disease II: Clinical Manifestations and Diagnostic Evaluation
349
Clinical manifestationsPeripheral Arterial Disease (PAD) manifests through a range of symptoms, from the characteristic intermittent claudication to atypical presentations and severe complications in advanced stages. Intermittent claudication, a hallmark symptom of PAD, presents as exercise-induced muscle pain that typically resolves within minutes of rest. This pain is reproducible and stems from inadequate blood flow, leading to the accumulation of lactic acid produced during anaerobic...
349
01:29Therapeutic Drug Monitoring: Affecting Factors
200
Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
200